Ecor1 Capital adds Five Prime Therapeutics Inc (FPRX) to its portfolio

Five Prime Therapeutics Inc (FPRX) : Ecor1 Capital added new position in Five Prime Therapeutics Inc during the most recent quarter end. The investment management firm now holds 286,612 shares of Five Prime Therapeutics Inc which is valued at $16,554,709 , the company said in a statement filed on Nov 14, 2016 with the SEC.Five Prime Therapeutics Inc makes up approximately 5.91% of Ecor1 Capital’s portfolio.

Other Hedge Funds, Including , Paradigm Asset Management Co added FPRX to its portfolio by purchasing 2,100 company shares during the most recent quarter which is valued at $121,296. Five Prime Therapeutics Inc makes up approx 0.02% of Paradigm Asset Management Co’s portfolio.Lord Abbett reduced its stake in FPRX by selling 83,288 shares or 42.42% in the most recent quarter. The Hedge Fund company now holds 113,062 shares of FPRX which is valued at $6,044,295. Five Prime Therapeutics Inc makes up approx 0.02% of Lord Abbett’s portfolio.Matarin Capital Management boosted its stake in FPRX in the latest quarter, The investment management firm added 80,898 additional shares and now holds a total of 117,303 shares of Five Prime Therapeutics Inc which is valued at $6,381,283. Five Prime Therapeutics Inc makes up approx 0.71% of Matarin Capital Management’s portfolio. Tower Research Capital (trc) sold out all of its stake in FPRX during the most recent quarter. The investment firm sold 114 shares of FPRX which is valued $5,700.Strs Ohio reduced its stake in FPRX by selling 3,700 shares or 16.44% in the most recent quarter. The Hedge Fund company now holds 18,800 shares of FPRX which is valued at $915,184.

Five Prime Therapeutics Inc opened for trading at $57.82 and hit $58.42 on the upside on Monday, eventually ending the session at $58, with a gain of 0.47% or 0.27 points. The heightened volatility saw the trading volume jump to 3,58,952 shares. Company has a market cap of $1,650 M.

On the company’s financial health, Five Prime Therapeutics Inc reported $-0.72 EPS for the quarter, missing the analyst consensus estimate by $ -0.21 based on the information available during the earnings call on Nov 3, 2016. Analyst had a consensus of $-0.51. The company had revenue of $6.70 million for the quarter, compared to analysts expectations of $7.19 million. The company’s revenue was up 13.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.93 EPS.

Many Wall Street Analysts have commented on Five Prime Therapeutics Inc. Five Prime Therapeutics Inc was Initiated by Citigroup to “Buy” on Oct 25, 2016.

Five Prime Therapeutics Inc. (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include FPA008 FPA144 and FP-1039/GSK3052230. FPA008 is an antibody that inhibits colony stimulating factor-1 (CSF1) receptor (CSF1R) that the Company is developing in rheumatoid arthritis. FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b) which the Company is developing to treat patients with gastric cancer. FP-1039/GSK3052230 is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation. Its partner GlaxoSmithKline is developing FP-1039/GSK3052230 to treat patients with squamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Five Prime Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Five Prime Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.